A first case report of using chimeric antigen receptor T-cell immunotherapy to treat high-risk smoldering multiple myeloma.

Liu, Yang; Duan, Wenbing; Huang, Xiaojun; Lu, Jin

Liu, Yang; Duan, Wenbing; Huang, Xiaojun; Lu, Jin.

Afiliación

Liu Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Duan W; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Huang X; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Lu J; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.

J Transl Int Med ; 11(3): 294-296, 2023 Sep.

Article en En | MEDLINE | ID: mdl-37662884

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: J Transl Int Med Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google